The global healthcare contract research outsourcing market size accounted for USD 46.53 billion in 2024, grew to USD 49.08 billion in 2025 and is predicted to surpass around USD 79.47 billion by 2034, representing a healthy CAGR of 5.50% between 2024 and 2034. The North America healthcare contract research outsourcing market size is calculated at USD 23.73 billion in 2024 and is expected to grow at a fastest CAGR of 5.59% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Healthcare Contract Research Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Healthcare Contract Research Outsourcing Market, by Type, 2024-2034
8.1.1. Drug Discovery
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Pre-Clinical
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Clinical
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Healthcare Contract Research Outsourcing Market, by Service, 2024-2034
9.1.1. Clinical Trial Services
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Regulatory Services
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Clinical Data Management & Biometrics
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Medical Writing
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Pharmacovigilance
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Site Management Protocol
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Healthcare Contract Research Outsourcing Market, by Application, 2024-2034
10.1.1. Oncology/Hematology
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Oncology/Hematology
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Autoimmune/Inflammation
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Central nervous system (CNS)
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Dermatology
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Infectious diseases
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Diabetes
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Pain
10.1.8.1. Market Revenue and Forecast (2021-2034)
10.1.9. Other
10.1.9.1. Market Revenue and Forecast (2021-2034)
11.1. Healthcare Contract Research Outsourcing Market, by End Use, 2024-2034
11.1.1. Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Biotechnology Companies
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Medical Device Companies
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Academic Institutes & Government Organizations
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Service (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End Use (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Service (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Service (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Service (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Service (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Service (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Service (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Service (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Service (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Service (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Service (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Service (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Service (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Service (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Service (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Service (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End Use (2021-2034)
13.1. Advanced Clinical
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Albany Molecular Research, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Charles River Laboratories International, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Clinipace
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Clintec
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Covance Clinical Biotech
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. CTI Clinical Trial & Consulting
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GVK Biosciences Private Limited
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. ICON Plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. IQVIA HOLDINGS INC.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample